|
Market Closed -
NYSE
01:30:00 28/08/2026 am IST
|
5-day change | 1st Jan Change | ||
| 3.180 USD | +0.63% |
|
-0.93% | +15.64% |
| 19/08 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 14/08 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 363 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 77.57% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 196.5 | 132.1 | 200.5 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 220.68% | -32.73% | 51.71% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -3.18x | -3x | -3.23x |
| PBR | - | - | - | 0.78x | 0.99x | 1.53x | 1.48x | 1.73x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.49x | 0.46x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 1,114x | 993x | 30x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 603x | 361x | 16.6x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.58x | -0.95x | -1.39x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.59x | -0.92x | -1.38x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.77x | -0.92x | -1.32x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -56.6% | -109% | -75.5% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -0.9994 | -1.061 | -0.986 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3258 | 0.3657 | 12.09 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -123.4 | -143.1 | -145.4 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -115.5 | -136.2 | -138.6 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 3.180 | 3.180 | 3.180 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 1,14,152 | - | - |
| Announcement Date | 21/09/21 | 01/05/23 | 28/03/24 | 26/03/25 | 16/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.18x | 603.02x | -1.58x | -.--% | 36Cr | |
| 34.55x | 6.16x | 18.31x | 0.93% | 5.11TCr | |
| -22.47x | 290.65x | -23.9x | -.--% | 4.74TCr | |
| 33.79x | 3.27x | 14.13x | -.--% | 4.32TCr | |
| 48.79x | 5.67x | 30.99x | -.--% | 4.24TCr | |
| 29.05x | 8.78x | 22.18x | 0.4% | 3.32TCr | |
| 34.78x | 5.7x | 25.92x | -.--% | 1.71TCr | |
| 24.34x | 2.11x | 9.14x | 1.11% | 1.48TCr | |
| 79.29x | 4.16x | 16.13x | -.--% | 1.42TCr | |
| Average | 28.77x | 103.28x | 12.37x | 0.27% | 2.93TCr | |
| Weighted average by Cap. | 27.56x | 57.54x | 12.40x | 0.29% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
